Cytokinetics develops muscle activators and inhibitors as potential treatments for debilitating diseases. Its drug candidates include omecamtiv mecarbil (Phase III trial), CK-136 (Phase I trial), CK-586 (Phase I trial), and aficamten (Phase III trial). The company focuses on small molecule drug candidates that impact muscle function and contractility. It has a strategic alliance with Ji Xing Pharmaceuticals Limited. Cytokinetics is headquartered in South San Francisco, California.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |